Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VV207
- Development stage
- Preclinical
- Lead developer
- Vigonvita Life Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VV207 is a preclinical-stage small molecule antiviral drug candidate being developed by Suzhou Vigonvita Biomedical for the treatment of adenovirus infections. It has demonstrated broad-spectrum antiviral activity in vitro against several viruses, including adenovirus, poxvirus, and human cytomegalovirus (HCMV). While the drug is currently positioned for adenovirus infection, its specific biological target and mechanism of action remain undisclosed by the company. Suzhou Vigonvita Biomedical is a China-based biopharmaceutical firm focusing on small-molecule drug discovery in viral infections and other therapeutic areas.
Beyond the preview
Go deeper on VV207.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VV207.